{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T19:19:52Z","timestamp":1788981592684,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K06707"],"award-info":[{"award-number":["21K06707"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13318-026-01005-1","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:06:14Z","timestamp":1781715974000},"page":"567-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of SLCO1B1 Gene Polymorphisms on Vadadustat Pharmacokinetics"],"prefix":"10.1007","volume":"51","author":[{"given":"Satoshi","family":"Yokoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-6423","authenticated-orcid":false,"given":"Takenori","family":"Niioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"1005_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","volume":"38","author":"RM Hanna","year":"2021","unstructured":"Hanna RM, Streja E, Kalantar-Zadeh K. Burden of anemia in chronic kidney disease: beyond erythropoietin. Adv Ther. 2021;38:52\u201375. https:\/\/doi.org\/10.1007\/s12325-020-01524-6.","journal-title":"Adv Ther"},{"key":"1005_CR2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279\u2013335.","journal-title":"Kidney Int Suppl"},{"key":"1005_CR3","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085\u201398. https:\/\/doi.org\/10.1056\/NEJMoa065485.","journal-title":"N Engl J Med"},{"key":"1005_CR4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1159\/000528443","volume":"53","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Anand S, Eckardt KU, et al. Overall adverse event profile of Vadadustat versus darbepoetin alfa for the treatment of anemia associated with chronic kidney disease in phase 3 trials. Am J Nephrol. 2022;53:701\u201310. https:\/\/doi.org\/10.1159\/000528443.","journal-title":"Am J Nephrol"},{"key":"1005_CR5","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s40265-022-01783-3","volume":"82","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Minutolo R, De Nicola L, Del Vecchio L. Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors. Drugs. 2022;82:1565\u201389. https:\/\/doi.org\/10.1007\/s40265-022-01783-3.","journal-title":"Drugs"},{"key":"1005_CR6","doi-asserted-by":"publisher","DOI":"10.2174\/0115680266366384250716121432","author":"F Shaikh","year":"2025","unstructured":"Shaikh F, Sharma S. Unveiling vadadustat: comprehensive review of its chemistry, pharmacology, bioanalysis, and patent landscape as a novel HIF-PH inhibitor. Curr Top Med Chem. 2025. https:\/\/doi.org\/10.2174\/0115680266366384250716121432.","journal-title":"Curr Top Med Chem"},{"key":"1005_CR7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-020-01383-z","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Vadadustat: first approval. Drugs. 2020;80:1365\u201371. https:\/\/doi.org\/10.1007\/s40265-020-01383-z.","journal-title":"Drugs"},{"key":"1005_CR8","unstructured":"Akebia Therapeutics. Vafseo [package insert] Cambridge, MA. 2024. https:\/\/www.vafseohcp.com\/pdf\/prescribing-information.pdf. Accessed 5 Sept 2025."},{"key":"1005_CR9","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","volume":"384","author":"KU Eckardt","year":"2021","unstructured":"Eckardt KU, Agarwal R, Aswad A, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021;384:1601\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2025956.","journal-title":"N Engl J Med"},{"key":"1005_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11255-022-03316-z","volume":"55","author":"Q Huang","year":"2023","unstructured":"Huang Q, Liao Z, Liu X, Xia Y, Wang J. Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis. Int Urol Nephrol. 2023;55:325\u201334. https:\/\/doi.org\/10.1007\/s11255-022-03316-z.","journal-title":"Int Urol Nephrol"},{"key":"1005_CR11","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1007\/s12325-025-03272-x","volume":"42","author":"M Nangaku","year":"2025","unstructured":"Nangaku M, Sasaki K, Bi J, et al. Real-world safety and effectiveness of vadadustat in patients with chronic kidney disease-related anemia: interim analysis of postmarketing surveillance in Japan. Adv Ther. 2025;42:4486\u2013509. https:\/\/doi.org\/10.1007\/s12325-025-03272-x.","journal-title":"Adv Ther"},{"key":"1005_CR12","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1681\/ASN.2020091311","volume":"32","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Kokado Y, et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol. 2021;32:1779\u201390. https:\/\/doi.org\/10.1681\/ASN.2020091311.","journal-title":"J Am Soc Nephrol"},{"key":"1005_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1097\/FTD.0000000000001238","volume":"46","author":"S Yokoyama","year":"2024","unstructured":"Yokoyama S, Nakagawa J, Shimada M, et al. Quantification of the plasma concentration of vadadustat by high-performance liquid chromatography with ultraviolet detection and ultra-performance liquid chromatography\u2013tandem mass spectrometry. Ther Drug Monit. 2024;46:813\u20139. https:\/\/doi.org\/10.1097\/FTD.0000000000001238.","journal-title":"Ther Drug Monit"},{"key":"1005_CR14","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/cpt.3342","volume":"116","author":"P Navarro-Gonzales","year":"2024","unstructured":"Navarro-Gonzales P, Ganz T, Pergola PE, Zuk A, Dykstra K. Pharmacokinetics, pharmacodynamics, and safety of vadadustat in healthy volunteers and patients with chronic kidney disease. Clin Pharmacol Ther. 2024;116:1052\u201361. https:\/\/doi.org\/10.1002\/cpt.3342.","journal-title":"Clin Pharmacol Ther"},{"key":"1005_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","volume":"26","author":"NS Sanghani","year":"2019","unstructured":"Sanghani NS, Haase VH. Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis. 2019;26:253\u201366. https:\/\/doi.org\/10.1053\/j.ackd.2019.04.004.","journal-title":"Adv Chronic Kidney Dis"},{"key":"1005_CR16","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/cpdd.927","volume":"10","author":"A Chavan","year":"2021","unstructured":"Chavan A, Burke L, Sawant R, Navarro-Gonzales P, Vargo D, Paulson SK. Effect of moderate hepatic impairment on the pharmacokinetics of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Clin Pharmacol Drug Dev. 2021;10:950\u20138. https:\/\/doi.org\/10.1002\/cpdd.927.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1005_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s13318-025-00947-2","volume":"50","author":"SM Jankovi\u0107","year":"2025","unstructured":"Jankovi\u0107 SM, Jankovi\u0107 SV. Clinical pharmacokinetics and pharmacodynamics of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Eur J Drug Metab Pharmacokinet. 2025;50:273\u201387. https:\/\/doi.org\/10.1007\/s13318-025-00947-2.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"1005_CR18","doi-asserted-by":"publisher","first-page":"DMD-AR-2023-001","DOI":"10.1124\/dmd.123.001630","volume":"52","author":"YA Bi","year":"2024","unstructured":"Bi YA, Jordan S, King-Ahmad A, et al. Low molecular weight acids and OATP1B mediated hepatic clearance: in vitro and in vivo evaluation using novel hypoxia-inducible factor prolyl hydroxylase inhibitors (Dustats). Drug Metab Dispos. 2024;52:DMD-AR-2023-001630. https:\/\/doi.org\/10.1124\/dmd.123.001630.","journal-title":"Drug Metab Dispos"},{"key":"1005_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","volume":"158","author":"A Kalliokoski","year":"2009","unstructured":"Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158:693\u2013705. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00430.x.","journal-title":"Br J Pharmacol"},{"key":"1005_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.2133\/dmpk.dmpk-11-rv-099","volume":"27","author":"T Nakanishi","year":"2012","unstructured":"Nakanishi T, Tamai I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet. 2012;27:106\u201321. https:\/\/doi.org\/10.2133\/dmpk.dmpk-11-rv-099.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1005_CR21","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.gpb.2016.03.008","volume":"14","author":"S Ahmed","year":"2016","unstructured":"Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genom Proteomics Bioinform. 2016;14:298\u2013313. https:\/\/doi.org\/10.1016\/j.gpb.2016.03.008.","journal-title":"Genom Proteomics Bioinform"},{"key":"1005_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41573-023-00877-1","volume":"23","author":"A Galetin","year":"2024","unstructured":"Galetin A, Brouwer KLR, Tweedie D, et al. Membrane transporters in drug development and as determinants of precision medicine. Nat Rev Drug Discov. 2024;23:255\u201380. https:\/\/doi.org\/10.1038\/s41573-023-00877-1.","journal-title":"Nat Rev Drug Discov"},{"key":"1005_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jchromb.2017.12.008","volume":"1073","author":"E Njumbe Ediage","year":"2018","unstructured":"Njumbe Ediage E, Dillen L, Vroman A, et al. Development of an LC\u2013MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions. J Chromatogr B Anal Technol Biomed Life Sci. 2018;1073:80\u20139. https:\/\/doi.org\/10.1016\/j.jchromb.2017.12.008.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"1005_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmpk.2021.100414","volume":"41","author":"K Maeda","year":"2021","unstructured":"Maeda K, Hisaka A, Ito K, et al. Classification of drugs for evaluating drug interaction in drug development and clinical management. Drug Metab Pharmacokinet. 2021;41:100414. https:\/\/doi.org\/10.1016\/j.dmpk.2021.100414.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1005_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/cpdd.1033","volume":"11","author":"SK Paulson","year":"2022","unstructured":"Paulson SK, Martinez J, Sawant R, Burke SK, Chavan A. Effect of phosphate binders and a dietary iron supplement on the pharmacokinetics of a single dose of vadadustat in healthy adults. Clin Pharmacol Drug Dev. 2022;11:475\u201385. https:\/\/doi.org\/10.1002\/cpdd.1033.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1005_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"key":"1005_CR27","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1124\/dmd.108.024208","volume":"37","author":"Y Saito","year":"2009","unstructured":"Saito Y, Sai K, Maekawa K, et al. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos. 2009;37:272\u20136. https:\/\/doi.org\/10.1124\/dmd.108.024208.","journal-title":"Drug Metab Dispos"},{"key":"1005_CR28","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/cpt.3062","volume":"114","author":"R Kikuchi","year":"2023","unstructured":"Kikuchi R, Chothe PP, Chu X, et al. Utilization of OATP1B biomarker coproporphyrin-I to guide drug-drug interaction risk assessment: evaluation by the pharmaceutical industry. Clin Pharmacol Ther. 2023;114:1170\u201383. https:\/\/doi.org\/10.1002\/cpt.3062.","journal-title":"Clin Pharmacol Ther"},{"key":"1005_CR29","unstructured":"Pharmaceuticals and Medical Devices Agency [PMDA]. Review Report. Vadadustat [Vafseo Tablets]. 2020. https:\/\/www.pmda.go.jp\/files\/000243933.pdf. Accessed 27 Feb 2026."},{"key":"1005_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-025-04367-x","volume":"26","author":"P Navarro-Gonzales","year":"2025","unstructured":"Navarro-Gonzales P, Chavan A, Wang D, Burke SK, Dykstra K. A randomized trial to evaluate the pharmacokinetics, pharmacodynamics, and safety of vadadustat in patients with anemia associated with chronic kidney disease receiving hemodialysis. BMC Nephrol. 2025;26:453. https:\/\/doi.org\/10.1186\/s12882-025-04367-x.","journal-title":"BMC Nephrol"},{"key":"1005_CR31","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10157-023-02432-z","volume":"28","author":"M Nangaku","year":"2024","unstructured":"Nangaku M, Ueta K, Nishimura K, Sasaki K, Hashimoto T. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies. Clin Exp Nephrol. 2024;28:391\u2013403. https:\/\/doi.org\/10.1007\/s10157-023-02432-z.","journal-title":"Clin Exp Nephrol"},{"key":"1005_CR32","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1007\/s10157-024-02511-9","volume":"28","author":"E Imai","year":"2024","unstructured":"Imai E, Imai A. The comparison of four hypoxia-inducible factor prolyl hydroxylase inhibitors on drug potency and cost for treatment in patients with renal anemia. Clin Exp Nephrol. 2024;28:1090\u20136. https:\/\/doi.org\/10.1007\/s10157-024-02511-9.","journal-title":"Clin Exp Nephrol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01005-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01005-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01005-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:56:24Z","timestamp":1788980184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01005-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01005-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Revised version of\nvideo abstract file updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Tomita has received speakers\u2019 bureau\/honoraria from Bayer. Dr. Nakamura has received speakers\u2019 bureau\/honoraria from Zeria Pharmaceutical, Otsuka Pharmaceutical, and Nippon Boehringer Ingelheim. Dr. Niioka has received research funding from Hitachi High-Tech. For the remaining authors, none were declared.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the principles of Declaration of Helsinki, and the study protocol was approved by the Ethics Committee of Hirosaki University Graduate School of Medicine, Japan (project identification code: 2021-139).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study participants provided written informed consent.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conception and design of this study, with T. Niioka taking the lead in conceptualization. Investigation, M. Shimada, N. Nakamura, and M. Ishiyama; plasma concentration measurements, S. Yokoyama, J. Nakagawa, and K. Ueno; formal analysis, S. Yokoyama, and J. Nakagawa; writing\u2014original draft preparation, S. Yokoyama; writing\u2014review and editing, H. Tomita and T. Niioka. All authors have read and approved the final manuscript.","order":6,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}